Prostate cancer deaths fall by a fifth in 20 years, says Cancer Research UK

Prostate cancer is second most common cause of cancer death among men, but progress has been made in treatmentDeath rates from prostate cancer have fallen by a fifth in the last two decades, according to Cancer Research UK.Prostate cancer is the second most common cause of cancer death among men and the fourth overall. But, the charity says, considerable progress has been made in life-saving treatment.Better treatment, more widespread use of hormone therapy, radical surgery and radiotherapy have all played a part in the drop in death rate.In the early 1990s, there were around 30 deaths per 100,000 men in the population, but new figures from CRUK show that has dropped to around 24 per 100,000.In actual numbers, deaths have gone up over that period, from 9,500 a year to 10,800 today. However, that is because men are generally living longer. Three-quarters of prostate cancer cases are diagnosed in men aged over 65.Some cases that could have been fatal are diagnosed earlier through the use of the PSA test – but this is a blunt instrument which does not differentiate between those cancers that will kill and those that will do no harm in the man's lifetime.Around 41,000 men are diagnosed with prostate cancer every year. CRUK says that while the drop in the death rate is good news, more progress is needed."This new report shows we've come a long way in improving the treatment of prostate cancer in the last couple of decades and improvements in how we treat prostate cancer...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: The Guardian News Health Medical research Society Cancer UK news Prostate cancer Source Type: news

Related Links:

ConclusionsNon-tissue diagnosis of prostate cancer, while rare, is not outside normal clinical practice and is strongly associated with advanced patient age, higher clinical stage, multiple comorbidities, and very high PSA levels.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
ConclusionCombined HDR-B/EBRT for the treatment of clinically localized prostate cancer provides superb clinical outcomes with excellent 5-year bRFS, dMFS, OS, and late GI/GU toxicity rates.
Source: Journal of Radiation Oncology - Category: Cancer & Oncology Source Type: research
ngione Mario Pulvirenti Antonino Romeo Ugo De Giorgi The therapeutic landscape of prostate cancer has expanded rapidly over the past 10 years, and there is now an even greater need to understand the biological mechanisms of resistance and to develop noninvasive biomarkers to guide treatment. The androgen receptor (AR) is known to be involved in the pathogenesis and progression of prostate cancer. Recently, highly sensitive next-generation sequencing and PCR-based methods for analyzing androgen receptor gene (AR) copy numbers (CN) and mutations in plasma were established in cell-free DNA (cfDNA) of patients with c...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Condition:   Metastatic Castration-resistent Prostate Cancer Interventions:   Drug: Docetaxel;   Drug: Abiraterone Acetate or Enzalutamide Sponsor:   National Cancer Institute, Naples Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS.—: Our understanding of neuroendocrine tumors of the prostate classification and diagnosis continues to evolve. These advances benefit the risk stratification and management of prostate cancer. PMID: 31644322 [PubMed - as supplied by publisher]
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Tags: Arch Pathol Lab Med Source Type: research
Conditions:   Positive Lymph Node;   Prostate Adenocarcinoma;   PSA Level Greater Than Zero;   Stage I Prostate Cancer AJCC v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC  v8;   Stage III Prostate Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage I...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: African Health | Cancer | Cancer & Oncology | Health | Hormonal Therapy | Hormones | Nurses | Nursing | Prostate Cancer | Research | Science